Kaposi’s Sarcoma – Cannabis Research

Kaposi's Sarcoma Research Dashboard


Primary Studies


Related Studies


Total Studies

Clinical Studies


Clinical Meta-analyses


Double-blind human trials


Clinical human trials

Pre-Clinical Studies




Animal studies


Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 12 studies associated with Kaposi's Sarcoma.

Here is a small sampling of Kaposi's Sarcoma studies by title:

Components of the Kaposi's Sarcoma Research Dashboard

  • Dosing information available for Kaposi's Sarcoma
  • Chemotype guidance for treating Kaposi's Sarcoma with cannabis
  • Synopsis of cannabis research for Kaposi's Sarcoma
  • Individual study details for Kaposi's Sarcoma

Ready to become a subscriber? Go to our PRICING page.

Select New Condition

Search By Keyword

Filter Condition

Members can filter by the following criteria:

  • Study Type
  • Chemotype
  • Cannabinoids & Endocannabinoids
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Kaposi's Sarcoma

Description of Kaposi's Sarcoma

Kaposi's sarcoma (KS) is an abnormal connective tissue mass, commonly presenting as multiple lesions on the skin. Moritz Kaposi first described the disease in the late nineteenth century. At that time, it was thought to be a cancer, a hereditary condition, or a viral infection. The confusion continued at the beginning of the AIDS epidemic in the early 1980s, when doctors considered it the signature disease in people diagnosed with AIDS (especially in the gay community). However, by 1994 it was established that KS is a cancer caused, in part, by a virus from the herpes family (the eighth human herpes virus), also called HHV-8 or Kaposi's sarcoma-associated herpes virus (KSHV). However, while KSHV is necessary for the development of Kaposi's sarcoma it is posited that other co-factors may also play a role. The allopathic community no longer considers KS to be an indication of AIDS when combined with a positive HIV test.

Disease Classification

Condition: Kaposi's Sarcoma
Disease Family: Cancer
Organ System: Integumentary System
ICD-10 Chapter: Neoplasms
ICD-10 Code: C46

Kaposi's Sarcoma Symptoms:

Discolored skin lesions (mostly purple, flat or raised, slow or fast growing), may or may not bleed or be inflamed, swollen, and painful

Also known as:


Drug Interactions

THC Interaction with Pharmaceutical Drugs

  • THC can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol, for example. 
  • THC is metabolized by and an inhibitor of a number of enzymatic liver pathways referred to as cytochrome P450. There are more than 50 enzymes belonging to this enzyme family, a number of which are responsible for the breakdown of common drugs such as antidepressants (e.g. amitriptyline, doxepine, fluvoxamine), antipsychotics (haloperidol, clozapine, stelazine), beta-blockers (e.g. propranolol), bronchodilators (e.g. theophylline), or bloodthinners (e.g. warfarin).  Thus patients taking these classes of medication may find that THC increases the concentration and effects of these drugs as well as the duration of their effects.
  • Clinical observation suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.

CBD Interaction with Pharmaceutical Drugs

  • CBD may alter action on metabolic enzymes (certain drug-transport mechanisms), and as such may alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects. 
  • Groups of drugs affected include: anti-epileptic drugs, psychiatric drugs, and drugs affecting metabolic enzymes, for example.
  • Clinical observations suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD

Dosing Considerations

THC Dosage Considerations

  • THC micro dose:  0.1 mg to 0.4 mg
  • THC low dose:  0.5 mg to 5 mg
  • THC medium dose:  6 mg to 20 mg
  • THC high dose:  21 mg to 50+ mg

CBD Dosage Considerations

  • CBD low dose:  0.4 mg to 19 mg
  • CBD medium dose: 20 mg to 99 mg
  • CBD high dose:  100 mg to 800+ mg (upper limits tested ~1,500mg)

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.